{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 20 July 2006\line \line {\b Roche 
in the first half of 2006: Outstanding growth} \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Download 
PDF: \u160?\u160?\u160?\u160?\u160?English (http://www.roche.com/mrhy06e.pdf) \u160?\u160?\u160?\u160?\u160?German (http://www.roche.com/mrhy06d.pdf) 
\u160?\u160?\u160?\u160?\u160?French (http://www.roche.com/mrhy06f.pdf) \u160?\u160?\u160?\u160?\u160?Spanish (http://www.roche.com/mrhy06sp.pdf)\line \line Half-Year 
Report 2006\line \line Presentation (http://www.roche.com/irp200706.pdf) (Investor Relations)\line \line \line {\b Group} \line \u8226? 
Group sales advance 16% to 20 billion Swiss francs, for a record half-year increase of 3 billion Swiss 
francs\line \u8226? Operating profit margin rises 2.4 percentage points to 29.2%\line \u8226? 
Net income increases 37% in Swiss francs to 4.5 billion Swiss francs thanks to strong operating performance 
and higher net financial income\line \line {\b Pharmaceuticals} \line \u8226? 
Pharmaceutical sales grow 19%, more than three times as fast as the global market\line \u8226? Cancer 
medicines deliver 48% growth, reinforcing Roche\u8217?s leadership in oncology\line \u8226? Operating 
profit margin rises 3.4 percentage points to 32.2%\line \u8226? Marketing approvals received for 
Herceptin in early-stage breast cancer and for MabThera in rheumatoid arthritis \line \u8226? Mircera 
filed for the treatment of renal anemia\line \u8226? Thirteen additional alliances signed, including 
agreements to co-develop three new research compounds from Chugai\line \line {\b Diagnostics} \line \u8226? 
Roche Diagnostics posts 4% rise in sales; growth accelerates in second quarter\line \u8226? As anticipated, 
investments in ongoing product launches and lower royalty income result in a decline in operating profit\line \u8226? 
Renewed Accu-Chek diabetes care portfolio experiencing strong uptake\line \line {\b Outlook 
for 2006} \line \u8226? Above-market sales growth, with double-digit increases for the Roche 
Group and the Pharmaceuticals Division\line \u8226? Target is for core earnings per share to grow 
ahead of sales\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 Unless otherwise stated, all growth rates 
are in local currencies / operating profit margins are stated before exceptional items\par}\line \line Commenting 
on the Group\u8217?s performance in the first half of 2006, Roche Chairman and CEO Franz B. Humer said: \u8216?Roche 
turned in another outstanding performance in the first half of 2006. Group sales rose 16% in local currencies 
\u8212? an impressive increase for any healthcare company \u8212? resulting in market share gains and a further 
improvement in earnings performance. Sales revenues grew organically by over 3 billion Swiss francs, 
driven primarily by our leading oncology products, the influenza medicine Tamiflu and our diagnostic 
brands. We are developing many of our marketed products for additional indications that will help fuel 
future growth for the Roche Group.\u8217?\line \line \line \line {\b Roche 
Group\line \line } {\b Organic sales growth tops 
3 billion Swiss francs\line \line } \line {\b Key 
figures in millions 
of CHF} \line 
		First halfFirst half        % change     % change    
	
		20062005in CHFin local cur.
	
		Sales19,84916,622+19+16
	
		EBITDAa)7,0615,592+26+23
	
		Operating profit before exceptional items5,8054,454+30+27
	
		Net income4,5433,328+37-
	
		Core EPSb) (in CHF)4.903.80+29-
	
		Employees (in full-time equivalents)70,52067,807c)+4-
	\line {\pard\f0\li0\ri0\sa360\sl360\fs18 a) 
EBITDA: Earnings before exceptional items and before financial income, financing costs, tax, depreciation 
and amortisation, including impairment. This corresponds to operating profit before exceptional items 
and before depreciation and amortisation, including impairment\line b) Core earnings per share 
and non-voting equity security (diluted) is calculated as shown on p. 48 of Roche\u8217?s 2006 Half-Year Report\line c) 
Employees 2005 as per 31 December 2005\par}\line \line \line Operationally 
and financially, the Roche Group had an outstanding first half-year. During the first six months of 
2006 Group sales increased significantly, advancing 16% in local currencies (19% in Swiss francs) to 
19.8 billion Swiss francs. Organic sales growth for the period totalled 3.2 billion Swiss francs. The 
Pharmaceuticals Division was the main growth driver. Its sales rose 19% in local currencies (23% in 
Swiss francs), over three times the global market, thanks primarily to continued strong demand for the 
anticancer medicines Herceptin, Avastin and MabThera/Rituxan and for the influenza medicine Tamiflu. 
In the Diagnostics Division interim sales showed a 4% increase in local currencies (8% in Swiss francs), 
with all business areas contributing to growth.\line \line This strong top-line 
growth had a very positive impact on the Group\u8217?s earnings performance. Operating profit before exceptional 
items rose 27% in local currencies to 5.8 billion Swiss francs. The corresponding operating profit margin 
improved significantly, increasing 2.4 percentage points to 29.2%, with sustained, robust sales growth 
more than offsetting increased investment in Roche\u8217?s highly promising development pipeline and in new 
product launches. \line \line {\b Improved operating margins for the Group 
and Pharma} \line The Group\u8217?s improved earnings performance was due primarily to the significantly 
higher operating profit recorded by the Pharmaceuticals Division. Its operating profit before exceptional 
items increased 35% in local currencies (38% in Swiss francs) to 5.0 billion Swiss francs, raising the 
division\u8217?s operating profit margin 3.4 percentage points to 32.2%. In the Diagnostics Division, as anticipated, 
interim operating profit before exceptional items was down by 7% in local currencies to 910 million 
Swiss francs. This resulted in a margin decrease of 2.5 percentage points, to 21.3%. Investment spending 
on the roll-out of new products and a decrease in royalty income were the main reasons for the lower 
operating profit figure.\line \line {\b Net income up by more than a third} \line The 
Group\u8217?s strong earnings performance is also reflected by other key indicators. EBITDA, for example, 
rose 23% in local currencies to 7.1 billion Swiss francs, and cash flow from operating activities (before 
taxes) reached 5.7 billion Swiss francs. Net financial income totalled 424 million Swiss francs, a significant 
improvement over the first half of 2005. The Group\u8217?s effective tax rate rose 3 percentage points, to 
27.3%, primarily as a result of a higher effective tax rate at Genentech. Net income increased substantially 
in the first six months, advancing 37% to 4.5 billion Swiss francs. The Group further strengthened its 
balance sheet. The ratio of equity to total assets is now 61%, and 87% of total assets are financed 
long term.\line \line {\b Outlook} \line Barring unforeseen 
events, Roche expects full-year sales and income for 2006 to be up significantly from 2005. The Group 
reaffirms the sales outlook announced at its annual media conference and increases the target on core 
earnings per share and non-voting equity security (core EPS): Sales in both the Pharmaceuticals and 
the Diagnostics Division are expected to grow ahead of the market in local currencies, with a continuing 
acceleration of Diagnostics\u8217? sales in the second half and continued double-digit growth for the Pharmaceuticals 
Division and the Group as a whole. The target is now for core EPS to grow above sales. \line \line \line \line {\b Pharmaceuticals 
Division} \line \line {\b Growth continues to significantly outpace 
market} \line \line 
		Key figuresIn millions of CHF% change in CHF% change in local currenciesAs % of sales
	
		Sales 15,5772319100
	
		- Roche Pharmaceuticals9,670211762
	
		- Genentech4,223473927
	
		- Chugai1,684-7-411
	
		EBITDA5,847343137.5
	
		Operating profit before exceptional items5,016383532.2
	
		Research and development2,736242117.6
	\line \line The 
Pharmaceuticals Division again posted very strong growth in the first half of 2006, with sales rising 
19% in local currencies (23% in Swiss francs), or more than three times the global market growth rate 
(5%). Growth was driven primarily by strong demand for the division\u8217?s oncology products, continued pandemic 
stockpiling of the influenza medicine Tamiflu, and sales of Bonviva/Boniva, for osteoporosis.\line \line Sales 
gains outpaced market growth almost fourfold in North America (23% vs 6%) and more than fourfold in 
Europe (23% vs 5%). In Japan sales declined 4% (vs a \u8211?1% market average), due mainly to significant 
government-mandated pharmaceutical price cuts and seasonal shifts in sales of Tamiflu compared with 
the prior-year period.\line \line Divisional operating profit before exceptional 
items advanced significantly, rising 35% in local currencies to 5.0 billion Swiss francs, and the operating 
profit margin on the same basis improved by 3.4 percentage points to 32.2%.\line \line {\b Oncology 
\u8212? Roche extends leadership further} \line The division\u8217?s oncology portfolio delivered 
first-half sales growth of 48%. All major brands contributed to this performance, which further consolidates 
Roche\u8217?s position as the world\u8217?s leading provider of cancer medicines.\line \line Sales 
of MabThera/Rituxan for non-Hodgkin\u8217?s lymphoma (NHL) continued to advance strongly in the first half 
of 2006. Growth was driven primarily by increasing use of the product in the first-line treatment of 
indolent NHL and aggressive NHL in Europe and in emerging markets such as Russia and China, while market 
penetration in the US remained high. In June and July, respectively, the Swiss and EU authorities approved 
MabThera as maintenance therapy in patients with relapsed or refractory follicular NHL, based on clinical 
data showing that the product reduces the risk of death by almost half compared with standard disease 
management.\line \line Worldwide sales of Herceptin, for HER2-positive breast cancer, 
more than doubled compared with the first half of 2005. Strong growth in the US and Europe was driven 
predominantly by uptake of the product in early-stage HER2-positive breast cancer. This indication was 
approved in the EU in May and is currently undergoing priority review in the US. Follow-up data from 
the large-scale HERA trial, presented at the 2006 meeting of the American Society of Clinical Oncology 
(ASCO) in June, showed that Herceptin given after standard chemotherapy reduces the risk of death by 
34% in patients with early breast cancer.\line \line Avastin, for colorectal cancer, 
posted impressive 119% sales growth, driven by strong demand in the US and across Europe. Avastin is 
the first and only anti-angiogenic agent that has been shown to improve patient survival in three major 
cancers: colorectal, non-small cell lung (NSCLC) and breast cancer. In June the FDA approved an application 
to expand the product\u8217?s label to include second-line treatment of metastatic colorectal cancer. Following 
a filing in April for non-squamous NSCLC, the most common form of lung cancer, Genentech filed a further 
application with the FDA in May for first-line use in advanced breast cancer. Roche applied in the EU 
for approval of this indication in July and is preparing to file further applications in the second 
half of 2006 for advanced lung cancer and to broaden the medicine\u8217?s current labelling for advanced colorectal 
cancer. In April Chugai filed the first marketing application in Japan for Avastin, for the treatment 
of advanced or recurrent colorectal cancer.\line \line Strong first-half growth 
in sales of Xeloda was driven mainly by increased market penetration in the adjuvant colon cancer setting 
(after surgery). Over 1 million patients have now benefited from treatment with this innovative oral 
anticancer agent. An EU filing for stomach cancer is planned for the second half of 2006. The results 
of a clinical trial of Xeloda in combination with oxaliplatin and Avastin in colon cancer are expected 
later this year and could eventually lead to further regulatory filings.\line \line Sales 
of Tarceva, a novel targeted treatment shown to extend the lives of patients with advanced lung and 
pancreatic cancer, continued to grow strongly. Tarceva is approved for the treatment of lung cancer 
in the EU, the US and many other countries. Following approval in the US late last year for advanced 
pancreatic cancer, the product is currently being reviewed by EU regulators for the same indication. 
In April Chugai filed in Japan for approval of Tarceva to treat advanced or recurrent NSCLC.\line \line {\b Anemia 
\u8212? healthy growth in a highly competitive market} \line Combined sales of Roche\u8217?s NeoRecormon 
and Chugai\u8217?s Epogin grew slightly in the first half-year. NeoRecormon again recorded good sales growth 
in a highly competitive market, maintaining its long-standing overall market leadership for the treatment 
of renal and cancer-related anemia in the regions where it is sold. Sales of NeoRecormon in cancer-related 
anemia continued to outgrow the market. In Japan, where Epogin remains the market leader in the renal 
anemia segment, sales revenues declined 6% due to government-mandated price cuts and reimbursement changes 
that resulted in a contraction of the overall anemia market.\line \line {\b Transplantation 
medicine \u8212? CellCept remains the leader} \line CellCept, a leading immunosuppressant worldwide 
for the prevention of transplant rejection, continued its solid overall sales growth. Combined sales 
of Valcyte and Cymevene, for prevention of dangerous cytomegalovirus infections, showed strong growth 
worldwide, advancing 16% to 223 million Swiss francs.\line \line {\b Virology 
\u8212? Tamiflu sales continue to grow strongly} \line Sales of Tamiflu grew 62%, driven by 
pandemic orders and seasonal sales. Due to an early flu season in Japan, the majority of seasonal sales 
in that market occurred in the fourth quarter of 2005, resulting in lower sales in the first half of 
2006 than in the prior-year period. Roche continues to expand efforts to increase and speed up availability 
of the medicine for influenza pandemic planning worldwide. In May Roche signed an agreement with the 
South African company Aspen to provide technical know-how for the production of a generic version of 
oseltamivir for pandemic use in Africa.\line \line Sales of the HIV medicine Fuzeon 
showed a healthy 19% gain to 143 million Swiss francs, with good growth in all marketing regions.\line \line Sales 
of Pegasys grew slightly in the first half-year, with the product maintaining its position as the world\u8217?s 
leading treatment for chronic hepatitis C. Copegus (ribavirin) sales declined significantly as a result 
of generic erosion, particularly in the US.\line \line {\b Rheumatoid 
arthritis \u8212? market launches in US and Europe} \line Following FDA approval for MabThera/Rituxan 
in rheumatoid arthritis (RA) in February and its rapid launch in this new indication by Genentech, early 
acceptance in the US has been very encouraging. Roche received EU marketing authorisation in July and 
European launches of MabThera in RA have commenced. MabThera/Rituxan provides lasting clinical benefits 
when patients are treated with repeated courses of only two infusions every six to twelve months. Strong 
radiographic data showing that MabThera can significantly inhibit joint damage in RA were presented 
at the Annual European Congress of Rheumatology (EULAR) in June.\line \line {\b Primary 
care \u8212? Bonviva/Boniva on track} \line Sales of once-monthly oral Bonviva/Boniva, for osteoporosis, 
increased to 167 million Swiss francs in the first half of 2006, with the product\u8217?s share of the US 
bisphosphonate market advancing to over 10%. Roche and its co-development partner GlaxoSmithKline have 
now launched the product in 42 countries worldwide. Launches in additional European markets are planned 
over the next few months. Following US approval and launch in January, Bonviva/Boniva Injection was 
approved in the EU in March. Given only once every three months, this new dosage form offers effective 
treatment to women unable to take or tolerate oral bisphosphonates.\line \line Xenical, 
for weight loss, showed double-digit growth. In January an FDA advisory committee recommended approval 
of orlistat 60 mg capsules as an over-the-counter medicine for weight loss in the US. Subject to final 
FDA approval, our co-marketing partner GlaxoSmithKline Consumer Healthcare plans to market the OTC product 
under the brand name Alli.\line \line {\b Major development activities 
\u8212? Mircera filed for approval in US and Europe} \line At the end of June 2006 the Pharmaceuticals 
Division\u8217?s R&D pipeline comprised 112 projects, including 57 new molecular entities and 55 additional 
indications. The Division currently has 36 projects in phase III development and ten projects in the 
registration phase. Nine major marketing applications were approved by US or EU regulators from January 
to early July 2006. Roche Pharmaceuticals plans to file five major new indications in the second half 
of this year.\line \line In the first half-year Roche filed marketing applications 
with the regulatory authorities in the US and the EU for Mircera (formerly C.E.R.A.) in its first indication, 
the treatment of renal anemia in patients on dialysis and not on dialysis. Mircera, the first of a new 
class of continuous erythropoietin receptor activators, has been studied using a two-week dosing interval 
for correction of anemia in untreated patients and using a once-monthly regimen for maintenance treatment. 
Clinical development of Mircera in cancer-related anemia is proceeding as planned.\line \line MabThera/Rituxan 
is currently being tested in patients with earlier stages of rheumatoid arthritis in an extensive development 
programme consisting of four phase III clinical trials. In April, based on excellent phase III data, 
Chugai filed applications with the Japanese health authorities to expand marketing approval of Actemra 
to include the treatment of adult RA and systemic onset juvenile idiopathic arthritis.\line \line In 
the first six months of 2006 Roche further strengthened its R&D pipeline with thirteen partnering 
transactions. Among these are three promising compounds currently in preclinical research at Chugai 
\u8212? two in oncology and one in diabetes.\line \line \line \line {\b Diagnostics 
Division\line } \line {\b On track for above-market 
growth} \line \line 
		Key figuresIn millions of CHF% change in CHF% change in local currenciesAs % of sales
	
		Sales4,27284100
	
		- Diabetes Care1,4284134
	
		- Centralized Diagnostics1,5357436
	
		- Molecular Diagnostics60910614
	
		- Near Patient Testing39315119
	
		- Applied Science30713107
	
		EBITDA1,333-1-431.2
	
		Operating profit before exceptional items910-4-721.3
	
		Research and development327-3-57.7
	\line \line Roche 
Diagnostics\u8217? sales rose 4% in local currencies (8% in Swiss francs) during the first half of 2006. Following 
first-quarter growth of 3%, divisional sales accelerated in the second quarter, advancing at a rate 
of 5%. Roche Molecular Diagnostics and Roche Centralized Diagnostics continued to generate the majority 
of growth, with revenues from these businesses up 6% and 4%, respectively, for the period. Roche Near 
Patient Testing and Roche Applied Science continued to perform strongly, both posting double-digit growth.\line \line The 
decline in the Division\u8217?s operating profit (before exceptional items) and operating margin reflects 
continued investment in the rollout of new products and continuing price pressure, especially in the 
clinical chemistry business. In addition, royalty income from PCR licences declined significantly due 
to the worldwide expiry of the basic PCR patents and one-off income from contracts in the first half 
of last year. At 21.3%, the operating profit margin remains well above the industry average.\line \line The 
rollout and increased market penetration of the renewed Accu-Chek portfolio in the blood glucose monitoring 
segment are expected to contribute to accelerated sales growth in the second half of the year.\line \line {\b Diabetes 
Care \u8212? Roche retains market leadership} \line With sales up 6% in a promising second quarter, 
Roche Diabetes Care maintained its global market leadership in a highly competitive segment, despite 
the continued impact of declining sales of the Accu-Chek Advantage meter in the United States. Growth 
in the first six months was fuelled primarily by strong growth of the Accu-Chek Compact line and Accu-Chek 
Aviva, which is becoming one of the main growth drivers for Diabetes Care. The strong uptake of integrated 
systems such as Accu-Chek Compact Plus in North America and the launches of Accu-Chek Compact, Accu-Chek 
Integra and Accu-Chek Multiclix in several markets in Asia also contributed to this result. High sales 
volumes for the Accu-Chek Active meter in Latin America and Asia Pacific and very positive uptake of 
the Accu-Chek Spirit insulin pump in Europe are expected to further strengthen Roche\u8217?s market leadership. 
Overall, the insulin delivery business outside the US grew 22% in the first six months.\line \line {\b Centralized 
Diagnostics \u8212? rollout of cobas 6000 under way} \line Helped by continued above-market 
growth in immunodiagnostics sales (12%), Roche Centralized Diagnostics retained its leadership in the 
clinical laboratories segment. Overall sales by this business area rose 4% in the first six months. 
The first three configurations of the new cobas 6000 series of modular analytical systems were launched 
in Europe in June and are scheduled for release in the United States in the third quarter of 2006. This 
next-generation platform, which will ultimately be available in seven different configurations, is ideally 
suited for use in medium-size laboratories, complementing the division\u8217?s current offerings for large 
and small-size labs. Two other Roche Diagnostics systems that are about to set new standards of performance 
and customer value are cobas c 111 (clinical chemistry and electrolyte analyser for extra-small-workload 
laboratories) and cobas e 411, both due to be launched in the fourth quarter of this year.\line \line {\b Molecular 
Diagnostics \u8212? strong blood-screening portfolio} \line Roche Molecular Diagnostics posted 
sales growth of 6% for the period, maintaining a market share of around 40% in an increasingly competitive 
sector. Sales of virology products continued to grow in line with the market, with blood screening also 
remaining a major contributor to growth. LightCycler SeptiFast Test, which can rapidly and reliably 
detect and identify 25 bacterial and fungal pathogens responsible for about 90% of all sepsis (blood 
poisoning) cases, was launched in Europe. In June Roche began rolling out the new automated cobas s 
201 modular blood screening system and comprehensive cobas TaqScreen MPX multiplex test across Europe. 
cobas TaqScreen MPX Test received CE (Conformit\u233? Europ\u233?enne) certification in March 2006. US biologics 
license applications (BLAs) for this test and for cobas TaqScreen WNV Test, for detection of West Nile 
virus, are planned for the third quarter of this year.\line \line {\b Near 
Patient Testing \u8212? blood glucose monitoring systems gain market share} \line Roche Near 
Patient Testing posted strong growth in the first half of 2006, with sales up 11%. Roche Diagnostics\u8217? 
leadership in coagulation monitoring was enhanced by the introduction of the CoaguChek XS system outside 
the United States. This instrument provides coagulation results on the spot, and virtually pain free, 
from a single drop of blood. Sales of blood glucose monitoring products advanced 35%, spurred by the 
trend towards tighter glycemic control in hospitalised patients and the fact that nearly all hospitals 
now perform blood glucose tests at patients\u8217? bedsides. The Accu-Chek Inform meter and Accu-Chek Advantage/Sensor 
strips are clear market leaders in this segment. Sales of cardiac assays rose 12%, helped by the roll-out 
of the Cardiac proBNP test.\line \line {\b Applied Science \u8212? strong demand 
for LightCycler systems} \line Roche Applied Science posted strong growth of 10% compared 
with the first half of 2005. The LightCycler 480 instrument, for high-throughput real-time PCR analysis, 
and the Genome Sequencer 20 system were the main growth drivers. GS20, the first product to result from 
the strategic alliance with 454 Life Sciences, is being used in an increasing number of applications 
in the attractive gene-sequencing market.\line \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche 
is one of the world\u8217?s leading research-focused healthcare groups in the fields of pharmaceuticals and 
diagnostics. As a supplier of innovative products and services for the early detection, prevention, 
diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines 
for cancer and transplantation and a market leader in virology. In 2005 sales by the Pharmaceuticals 
Division totalled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion 
Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic 
alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional 
information about the Roche Group is available on the Internet www.roche.com (http://www.roche.com).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 \line All 
trademarks used or mentioned in this release are protected by law.\par}\line \line Annex (http://www.roche.com/mrhy06ane.pdf)\line \line \line {\b Additional 
information} \line - Media release including a full set of tables\line - 
Half-Year 
Report 2006\line - Presentation (http://www.roche.com/irp200706.pdf) (Investor Relations)\line - 
Roche Pharma Pipeline\line - Date of publication of the nine months sales 
release 2006: 17 October (tentative)\line \line \line {\i Disclaimer: 
Cautionary statement regarding forward-looking statements\line This document contains certain 
forward-looking statements. These forward-looking statements may be identified by words such as \u8216?believes\u8217?, 
\u8216?expects\u8217?, \u8216?anticipates\u8217?, \u8216?projects\u8217?, \u8216?intends\u8217?, \u8216?should\u8217?, \u8216?seeks\u8217?, \u8216?estimates\u8217?, \u8216?future\u8217? or similar 
expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors 
may cause actual results to differ materially in the future from those reflected in forward-looking 
statements contained in this document, among others: (1) pricing and product initiatives of competitors; 
(2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining 
regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and 
general financial market conditions; (5) uncertainties in the discovery, development or marketing of 
new products or new uses of existing products, including without limitation negative results of clinical 
trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased 
government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate 
protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; 
and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not 
a profit forecast and should not be interpreted to mean that Roche\u8217?s earnings or earnings per share 
for 2006 or any subsequent period will necessarily match or exceed the historical published earnings 
or earnings per share of Roche.} \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}